Primus Reports
Budget 2022: Pharma sector wants tax breaks, R&D incentives
29-Jan-2022
Anurag Singh, managing director of a consulting firm Primus Partners added that a combination of high-impact schemes have been put in place for pharma-sector recently, including PLIs for pharma, key starting materials (KSM), API, medical devices, scheme for promotion of bulk drug parks, medical device parks, etc. The net impact of the pandemic and supply chain disruptions in China have been favourable for the Indian pharma sector.
Explore Related Insights
- Bharat NCAP: What It Means For the Auto Industry
- GST collection to remain robust due to festive season; buoyancy may absorb external shock
- Digital Learning Helps Save 2020 From Becoming A Void Year For Students But Challenges Remain: Reports
- India Blockchain Forum launches Web3.0 ecosystem directory